Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application

References

• BerryDJHarmsenWSCabanelaMEMorreyBFTwenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral componentsJ Bone Joint Surg Am200284217117711861721
   PubMed Web of Science ®Google Scholar
• KeenerJDCallaghanJJGoetzDDPedersonDRSullivanPMJohnstonRCTwenty-five-year results after Charnley total hip arthroplasty in patients less than fifty years old: a concise follow-up of a previous reportJ Bone Joint Surg Am200385A61066107212784004
   PubMed Web of Science ®Google Scholar
• FenderDHarperWMGreggPJOutcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip registerJ Bone Joint Surg Br199981457758110463724
   PubMedGoogle Scholar
• SethiRKNeavynMJRubashHEShanbhagASMacrophage response to cross-linked and conventional UHMWPEBiomaterials200324152561257312726710
   PubMed Web of Science ®Google Scholar
• SchwarzEMWhat potential biologic treatments are available for osteolysis?J Am Acad Orthop Surg200816 Suppl 1S727518612019
   PubMed Web of Science ®Google Scholar
• PollicePFRosierRNLooneyRJPuzasJESchwarzEMO’KeefeRJOral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint componentsJ Bone Joint Surg Am200183A71057106111451976
   PubMed Web of Science ®Google Scholar
• ChildsLMGoaterJJO’KeefeRJSchwarzEMEfficacy of etanercept for wear debris-induced osteolysisJ Bone Miner Res200116233834711204434
   PubMed Web of Science ®Google Scholar
• YatsunamiJHayashiSFourteen-membered ring macrolides as antiangiogenic compoundsAnticancer Res2001216B4253425811908678
   PubMed Web of Science ®Google Scholar
• CervinAThe anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitisActa Otolaryngol20011211839211270500
   PubMed Web of Science ®Google Scholar
• Giamarellos-BourboulisEJMacrolides beyond the conventional antimicrobials: a class of potent immunomodulatorsInt J Antimicrob Agents2008311122017935949
   PubMed Web of Science ®Google Scholar
• KudohSErythromycin treatment in diffuse panbronchiolitisCurr Opin Pulm Med1998421161219612675
   PubMedGoogle Scholar
• KudohSAzumaAYamamotoMIzumiTAndoMImprovement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycinAm J Respir Crit Care Med19981576 Pt 1182918329620913
   PubMed Web of Science ®Google Scholar
• RenWPLiXYChenBDWooleyPHErythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NFkB activityJ Orthop Res2004221212914656655
   PubMed Web of Science ®Google Scholar
• RenWPBinWMaytonLWooleyPHErythromycin (EM) inhibits wear debris-induced inflammatory osteolysis in a murine modelJ Orthop Res200624228029016435361
   PubMed Web of Science ®Google Scholar
• RenWBlasierRPengXShiTWooleyPHMarkelDEffect of oral erythromycin therapy in patients with aseptic loosening of joint prosthesesBone200944467167719154802
   PubMed Web of Science ®Google Scholar
• RenWZhangRHawkinsMShiTMarkelDCEfficacy of periprosthetic erythromycin delivery for wear debris-induced inflammation and osteolysisInflamm Res201059121091109720607583
   PubMed Web of Science ®Google Scholar
• KhabrievRUPopkovVAReshetnyakVYKrasnyukIISolubility of erythromicin from solid dispersionsPharm Chem J200943113643
   Web of Science ®Google Scholar
• JayaramanSCRamachandranCWeinerNTopical delivery of erythromycin from various formulations: an in vivo hairless mouse studyJ Pharm Sci19968510108210848897275
   PubMed Web of Science ®Google Scholar
• DavisMEBrewsterMECyclodextrin-based pharmaceutics: past, present and futureNat Rev Drug Discov20043121023103515573101
   PubMed Web of Science ®Google Scholar
• ShimpiSChauhanBShimpiPCyclodextrins: application in different routes of drug administrationActa Pharm200555213915616179128
   PubMedGoogle Scholar
• LiuXMWiswallATRutledgeJEOsteotropic beta-cyclodextrin for local bone regenerationBiomaterials200829111686169218199479
   PubMed Web of Science ®Google Scholar
• FerrariFSorrentiMRossiSVancomycin-triacetyl cyclodextrin interaction products for prolonged drug deliveryPharm Dev Technol2008131657318300101
   PubMed Web of Science ®Google Scholar
• SonglXDuFYGuoXQPanSZFormation, characterization, and thermal degradation behavior of a novel tricomponent aggregate of beta-cyclodextrin, ferrocene, and polypropylene glycolJ Phys Chem B201011441738174420055361
   PubMed Web of Science ®Google Scholar
• MatilainenLMaunuSLPajanderJThe stability and dissolution properties of solid glucagon/gamma-cyclodextrin powderEur J Pharm Sci2009364–541242019059479
   PubMed Web of Science ®Google Scholar
• SzejtliJCyclodextrins and Their Inclusion Complex2nd edBudapest, HungaryAkademiai Kiado1982
   Google Scholar
• LafontFTran VanNGHanadaKSansonettiPvan der GootFGInitial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interactionEMBO J200221174449445712198147
   PubMed Web of Science ®Google Scholar
• PohBLTheeKKNo distinction between host and guest – the case of cyclodextrins complexing with disodium 1,8-disulfonato- 3,4,5,6-acridinetetracarboxylic acidTetrahedron Lett1996374174337436
   Web of Science ®Google Scholar
• PohBLTanCMComplexation of amino-acids by cyclotetrachromotropylene in aqueous-solution – importance of ch-pi and pi-pi interactionsTetrahedron1994501134533462
   Web of Science ®Google Scholar
• PohBLCyclodextrins (alpha-, beta-, and gamma-) as guests to calcichrome (calcion) in waterTetrahedron199652331097910984
   Web of Science ®Google Scholar
• WongmekiatATozukaYMoribeKOguchiTYamamotoKPreparation of drug nanoparticles by co-grinding with cyclodextrin: formation mechanism and factors affecting nanoparticle formationChem Pharm Bull (Tokyo)200755335936317329871
   PubMed Web of Science ®Google Scholar
• FloreyCAnalytical Profiles of Drug SubstancesNew York, NYAcademic Press Inc1979
   Google Scholar
• YanTRiggsBLBoyleWJKhoslaSRegulation of osteoclastogenesis and RANK expression by TGF-beta1J Cell Biochem200183232032511573248
   PubMed Web of Science ®Google Scholar
• WoodDJHruskaFESaengerWH-1 NMR-study of inclusion of aromatic-molecules in alpha-cyclodextrinJ Am Chem Soc197799617351740
   Web of Science ®Google Scholar
• EverettJRHattonIKTylerJWConformational-analysis of erythromycin a derivatives – a predictive method using NMR chemical-shift and coupling-constant dataMagn Reson Chem1990282114118
   Web of Science ®Google Scholar
• BenderMLKomiyamaMCyclodextrin ChemistryNew York, NYSpringer-Verlag1978
   Google Scholar
• LachJLCohenJInteraction of pharmaceuticals with schardinger dextrins II. Interaction with selected compoundsJ Pharm Sci196352213714213927899
   PubMed Web of Science ®Google Scholar
• VanEttenRLSebatianJFClowesGABenderMLAcceleration of phenyl ester cleavage by cycloamyloses: a model for enzymatic specificityJ Am Chem Soc1967891332423253
   Web of Science ®Google Scholar
• CramerFHettlerHInclusion compounds of cyclodextrinsNaturwissenschaften196754246256324298643
   PubMed Web of Science ®Google Scholar
• ManorPCSaengerWWater molecule in hydrophobic surroundings: structure of a-cyclodextrin-hexahydrateNature1972237392393
   Web of Science ®Google Scholar
• GuoQXLiuLCaiWSJiangYLiuYCDriving force prediction for inclusion complexation of alpha-cyclodextrin with benzene derivatives by a wavelet neural networkChem Phys Lett19982904–6514518
   Web of Science ®Google Scholar
• TakeoKKugeTComplexes of starchy materials with organic compounds part III. X-ray studies on amylose and cyclodextrin complexesAgric Biol Chem19693311741180
   Web of Science ®Google Scholar
• AreeTJacobJSaengerWHoierHCrystal structure of alpha- cyclodextrin- acetonitrile-hexahydrateCarbohydr Res19983073–41911979675363
   PubMed Web of Science ®Google Scholar
• StigterMBezemerJdeGKLayrollePIncorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacyJ Control Release200499112713715342186
   PubMed Web of Science ®Google Scholar
• ZhangRXuDLanderyouTEctopic bone formation using osteogenic protein-1 carried by a solution precipitated hydroxyapatiteJ Biomed Mater Res A200471341241815472924
   PubMed Web of Science ®Google Scholar
• ZhangRAnYTothCADraughnRADimaanoNMHawkinsMVOsteogenic protein-1 enhances osseointegration of titanium implants coated with peri-apatite in rabbit femoral defectJ Biomed Mater Res B Appl Biomater200471240841315389505
   PubMed Web of Science ®Google Scholar
• ButlerMNWeberWJAccelerated transformation and deactivation of erythromycin in superheated water. 1. Temperature effects, transformation rates, and the impacts of dissolved organic matterEnviron Sci Technol20053972294230015871267
   PubMed Web of Science ®Google Scholar
• KongYYYoshidaHSarosiIOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature199939767173153239950424
   PubMed Web of Science ®Google Scholar
• LaceyDLTimmsETanHLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell19989321651769568710
   PubMed Web of Science ®Google Scholar
• RenWWuBPengXHuaJHaoHNWooleyPHImplant wear induces inflammation, but not osteoclastic bone resorption, in RANK(−/−) miceJ Orthop Res20062481575158616779834
   PubMed Web of Science ®Google Scholar
• GehrkeTSersCMorawietzLReceptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis looseningScand J Rheumatol200332528729414690142
   PubMed Web of Science ®Google Scholar
• GreenfieldEMBiYRagabAAGoldbergVMvan de MotterRRThe role of osteoclast differentiation in aseptic looseningJ Orthop Res20022011811855378
   PubMed Web of Science ®Google Scholar
• SabokbarAFujikawaYNealeSMurrayDWAthanasouNAHuman arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cellsAnn Rheum Dis19975674144209486003
   PubMed Web of Science ®Google Scholar
• IrieTUekamaKPharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluationJ Pharm Sci19978621471629040088
   PubMed Web of Science ®Google Scholar